This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ide, T. Articles by Yamada, N. Search for Related Content PubMed PubMed Citation Articles by Ide, T. Articles by Yamada, N. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH

Cross-Talk between Peroxisome Proliferator-Activated Receptor (PPAR) and Liver X Receptor (LXR) in Nutritional Regulation of Fatty Acid Metabolism. II. LXRs Suppress Lipid Degradation Gene Promoters through Inhibition of PPAR Signaling

Department of Internal Medicine (T.I., H.S., T.M., M.N., S.Y., A.T., H.S., N.S.), Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305-8575, Japan; and Department of Metabolic Diseases (T.Y., N.Y., M.A.-K., Y.I., S.T., K.O., T.G., J.O., S.I.), Faculty of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan

Address all correspondence and requests for reprints to: Hitoshi Shimano, M.D., Ph.D., Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. E-mail: shimano-tky{at}umin.ac.jp.

Fatty acid metabolism is transcriptionally regulated by two reciprocal systems: peroxisome proliferator-activated receptor (PPAR) controls fatty acid degradation, whereas sterol regulatory element-binding protein-1c activated by liver X receptor (LXR) regulates fatty acid synthesis. To explore potential interactions between LXR and PPAR, the effect of LXR activation on PPAR signaling was investigated. In luciferase reporter gene assays, overexpression of LXR or ß suppressed PPAR-induced peroxisome proliferator response element-luciferase activity in a dose-dependent manner. LXR agonists, T0901317 and 22(R)-hydroxycholesterol, dose dependently enhanced the suppressive effects of LXRs. Gel shift assays demonstrated that LXR reduced binding of PPAR/retinoid X receptor (RXR) to peroxisome proliferator response element. Addition of increasing amounts of RXR restored these inhibitory effects in both luciferase and gel shift assays, suggesting the presence of RXR competition. In vitro protein binding assays demonstrated that activation of LXR by an LXR agonist promoted formation of LXR/RXR and, more importantly, LXR/PPAR heterodimers, leading to a reduction of PPAR/RXR formation. Supportively, in vivo administration of the LXR ligand to mice and rat primary hepatocytes substantially decreased hepatic mRNA levels of PPAR-targeted genes in both basal and PPAR agonist-induced conditions. The amount of nuclear PPAR/RXR heterodimers in the mouse livers was induced by treatment with PPAR ligand, and was suppressed by superimposed LXR ligand. Taken together with data from the accompanying paper (Yoshikawa, T., T. Ide, H. Shimano, N. Yahagi, M. Amemiya-Kudo, T. Matsuzaka, S. Yatoh, T. Kitamine, H. Okazaki, Y. Tamura, M. Sekiya, A. Takahashi, A. H. Hasty, R. Sato, H. Sone, J. Osuga, S. Ishibashi, and N. Yamada, Endocrinology 144:1240–1254) describing PPAR suppression of the LXR-sterol regulatory element-binding protein-1c pathway, we propose the presence of an intricate network of nutritional transcription factors with mutual interactions, resulting in efficient reciprocal regulation of lipid degradation and lipogenesis.

NURSA Molecule Pages Link:

Nuclear Receptors:   PPARα  |  PPARγ  |  LXRβ  |  LXRα  |  RXRβ

Coregulators:   CBP  |  p300

Ligands:   22α-Hydroxycholesterol  |  T0901317  |  Pirinixic acid

This article has been cited by other articles:

				S. Colin, E. Bourguignon, A.-B. Boullay, J.-J. Tousaint, S. Huet, F. Caira, B. Staels, S. Lestavel, J.-M. A. Lobaccaro, and P. Delerive Intestine-Specific Regulation of PPAR{alpha} Gene Transcription by Liver X Receptors Endocrinology, October 1, 2008; 149(10): 5128 - 5135. [Abstract] [Full Text] [PDF]

				N. Anderson and J. Borlak Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis Pharmacol. Rev., September 1, 2008; 60(3): 311 - 357. [Abstract] [Full Text] [PDF]

				H. Wang, Y. Zhang, E. Yehuda-Shnaidman, A. V. Medvedev, N. Kumar, K. W. Daniel, J. Robidoux, M. P. Czech, D. J. Mangelsdorf, and S. Collins Liver X Receptor {alpha} Is a Transcriptional Repressor of the Uncoupling Protein 1 Gene and the Brown Fat Phenotype Mol. Cell. Biol., April 1, 2008; 28(7): 2187 - 2200. [Abstract] [Full Text] [PDF]

				E. Grenier, F. S. Maupas, J.-F. Beaulieu, E. Seidman, E. Delvin, A. Sane, E. Tremblay, C. Garofalo, and E. Levy Effect of retinoic acid on cell proliferation and differentiation as well as on lipid synthesis, lipoprotein secretion, and apolipoprotein biogenesis Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1178 - G1189. [Abstract] [Full Text] [PDF]

				C. G. Woods, J. P. Vanden Heuvel, and I. Rusyn Genomic Profiling in Nuclear Receptor-Mediated Toxicity Toxicol Pathol, June 1, 2007; 35(4): 474 - 494. [Abstract] [Full Text] [PDF]

				Y.-Y. Liu, R. S. Heymann, F. Moatamed, J. J. Schultz, D. Sobel, and G. A. Brent A Mutant Thyroid Hormone Receptor {alpha} Antagonizes Peroxisome Proliferator-Activated Receptor {alpha} Signaling in Vivo and Impairs Fatty Acid Oxidation Endocrinology, March 1, 2007; 148(3): 1206 - 1217. [Abstract] [Full Text] [PDF]

				M. C. Rudolph, J. L. McManaman, T. Phang, T. Russell, D. J. Kominsky, N. J. Serkova, T. Stein, S. M. Anderson, and M. C. Neville Metabolic regulation in the lactating mammary gland: a lipid synthesizing machine Physiol Genomics, February 12, 2007; 28(3): 323 - 336. [Abstract] [Full Text] [PDF]

				R. J Deckelbaum, T. S Worgall, and T. Seo n-3 Fatty acids and gene expression Am. J. Clinical Nutrition, June 1, 2006; 83(6): S1520 - 1525S. [Abstract] [Full Text] [PDF]

				M. Loffler, M. Bilban, M. Reimers, W. Waldhausl, and T. M. Stulnig Blood Glucose-Lowering Nuclear Receptor Agonists Only Partially Normalize Hepatic Gene Expression in db/db Mice J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 797 - 804. [Abstract] [Full Text] [PDF]

				S. K. Cheema, A. Agarwal-Mawal, C. M. Murray, and S. Tucker Lack of stimulation of cholesteryl ester transfer protein by cholesterol in the presence of a high-fat diet J. Lipid Res., November 1, 2005; 46(11): 2356 - 2366. [Abstract] [Full Text] [PDF]

				C. Le May, M. Cauzac, C. Diradourian, D. Perdereau, J. Girard, A.-F. Burnol, and J.-P. Pegorier Fatty Acids Induce L-CPT I Gene Expression through a PPAR{alpha}-Independent Mechanism in Rat Hepatoma Cells J. Nutr., October 1, 2005; 135(10): 2313 - 2319. [Abstract] [Full Text] [PDF]

				M. L. Fernandez and K. L. West Mechanisms by which Dietary Fatty Acids Modulate Plasma Lipids1 J. Nutr., September 1, 2005; 135(9): 2075 - 2078. [Abstract] [Full Text] [PDF]

				S. P. Anderson, C. Dunn, A. Laughter, L. Yoon, C. Swanson, T. M. Stulnig, K. R. Steffensen, R. A.S. Chandraratna, J.-A. Gustafsson, and J. C. Corton Overlapping Transcriptional Programs Regulated by the Nuclear Receptors Peroxisome Proliferator-Activated Receptor {alpha}, Retinoid X Receptor, and Liver X Receptor in Mouse Liver Mol. Pharmacol., December 1, 2004; 66(6): 1440 - 1452. [Abstract] [Full Text] [PDF]

				T. Kino and G. P. Chrousos Combating Atherosclerosis With LXR{alpha} And PPAR{alpha} Agonists: Is Rational Multitargeted Polypharmacy the Future of Therapeutics in Complex Diseases? Mol. Interv., October 1, 2004; 4(5): 254 - 257. [Abstract] [Full Text] [PDF]

				C. G Taylor and P. Zahradka Dietary conjugated linoleic acid and insulin sensitivity and resistance in rodent models Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1164S - 1168S. [Abstract] [Full Text] [PDF]

				J. M. Paterson, N. M. Morton, C. Fievet, C. J. Kenyon, M. C. Holmes, B. Staels, J. R. Seckl, and J. J. Mullins Metabolic syndrome without obesity: Hepatic overexpression of 11{beta}-hydroxysteroid dehydrogenase type 1 in transgenic mice PNAS, May 4, 2004; 101(18): 7088 - 7093. [Abstract] [Full Text] [PDF]

				D. S. Ng, C. Xie, G. F. Maguire, X. Zhu, F. Ugwu, E. Lam, and P. W. Connelly Hypertriglyceridemia in Lecithin-cholesterol Acyltransferase-deficient Mice Is Associated with Hepatic Overproduction of Triglycerides, Increased Lipogenesis, and Improved Glucose Tolerance J. Biol. Chem., February 27, 2004; 279(9): 7636 - 7642. [Abstract] [Full Text] [PDF]

				G. F. Gbaguidi and L. B. Agellon The inhibition of the human cholesterol 7{alpha}-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor {alpha} and peroxisome proliferator-activated receptor {alpha} heterodimer Nucleic Acids Res., February 11, 2004; 32(3): 1113 - 1121. [Abstract] [Full Text] [PDF]